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AbstrAct
Introduction Rising burden of cardiovascular disease 
(CVD) and diabetes is a major challenge to the health 
system in India. Innovative approaches such as mobile 
phone technology (mHealth) for electronic decision 
support in delivering evidence-based and integrated 
care for hypertension, diabetes and comorbid depression 
have potential to transform the primary healthcare 
system.
Methods and analysis mWellcare trial is a multicentre, 
cluster randomised controlled trial evaluating the clinical 
and cost-effectiveness of a mHealth system and nurse 
managed care for people with hypertension and diabetes 
in rural India. mWellcare system is an Android-based 
mobile application designed to generate algorithm-based 
clinical management prompts for treating hypertension 
and diabetes and also capable of storing health records, 
sending alerts and reminders for follow-up and adherence 
to medication. We recruited a total of 3702 participants 
from 40 Community Health Centres (CHCs), with ≥90 at 
each of the CHCs in the intervention and control (enhanced 
care) arms. The primary outcome is the difference in mean 
change (from baseline to 1 year) in systolic blood pressure 
and glycated haemoglobin (HbA1c) between the two 
treatment arms. The secondary outcomes are difference 
in mean change from baseline to 1 year in fasting plasma 
glucose, total cholesterol, predicted 10-year risk of CVD, 
depression, smoking behaviour, body mass index and 
alcohol use between the two treatment arms and cost-
effectiveness.
Ethics and dissemination The study has been approved 
by the institutional Ethics Committees at Public Health 
Foundation of India and the London School of Hygiene 
and Tropical Medicine. Findings will be disseminated 
widely through peer-reviewed publications, conference 
presentations and other mechanisms.
trial registration mWellcare trial is registered with  
Clinicaltrial. gov (Registration number NCT02480062; Pre-
results) and Clinical Trial Registry of India (Registration 
number CTRI/2016/02/006641). The current version of the 
protocol is Version 2 dated 19 October 2015 and the study 
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Protocol
strengths and limitations of the study
 ► mWellcare trial is the first study in India, assessing 
the effectiveness of mHealth technology for 
integrated management of hypertension and 
diabetes at primary care level in a public health 
setting.
 ► The study follows a cluster randomised controlled 
trial design.
 ► The study uses nurse for shifting/sharing some of 
the patient management tasks from physicians.
 ► The Intervention provides clinical decision support 
to physician for standardised and integrated 
management of hypertension and diabetes along 
with comorbid conditions such as depression and 
alcohol use disorder.
 ► The mWellcare intervention is being implemented in 
the real-world scenario aimed at using the existing 
human resource with an aim of scalability.
 ► Effectiveness of the trial will also depend on the 
availability of drugs recommended by the decision 
support system. Drugs are supplied by the state 
government and there are variations in availability 
across the state and districts, although such 
variations are likely to affect both arms equally.
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sponsor is Public Health Foundation of India, Gurgaon, India (www. phfi. 
org).
bAckground And rAtIonAlE
Cardiovascular disease (CVD) and diabetes are the 
leading causes of premature (<60 years) adult deaths 
in India with projections indicating almost threefold 
increase to 18 million premature years of life lost by 2030, 
a greater loss of life than the combined projected burdens 
for China, Russia and the USA.1 2 CVD and diabetes will 
result in $2.32 trillion loss in national income in India 
between 2012 and 2030.3 Primary care is considered as 
the appropriate setting for the prevention and control of 
chronic conditions and it is being strengthened through 
the National Programme for Prevention and Control 
of cancer, diabetes, cardiovascular diseases and stroke 
(NPCDCS) in India.2 4 5
The telecom industry in India has grown exponentially 
over past 15 years, from under 3.6 million mobile phone 
subscribers in March 2001 to over a billion subscribers in 
December 2015.6 Mobile phones and other mobile tech-
nologies require less infrastructure than other eHealth 
systems, making them a promising investment for devel-
oping countries wanting to strengthen and transform their 
weak health systems, and to overcome healthcare worker 
shortages.7–9 Systematic reviews have demonstrated a lack 
of robust evaluations of the impact of mHealth.10–14 This 
lack of adequate evaluations led to need to provide robust 
evidence on the safety, benefits and associated cost-ef-
fectiveness of mHealth systems.8 9 15 16 Systematic review 
and meta-analysis of studies evaluating role of decision 
support system for prevention of CVD show paucity of 
well-designed studies on patient outcomes.17 In addition, 
there is a dearth of evidence on effect of task shifting/
sharing strategies for CVD risk reduction and chronic 
disease management.18 19 Through mWellcare we propose 
to enhance the quality of hypertension and diabetes care 
at primary care level in India by using mobile phone tech-
nology that implements a clinical decision support system 
and electronic health records for the use of healthcare 
professionals. The effectiveness of the mHealth system 
will be tested on a range of clinical and process-of-care 
indicators.
MEthods And AnAlysIs
Objective
The primary objective is to evaluate mWellcare system in 
two states in India over a 12-month period to determine its 
effectiveness on the management of patients with hyper-
tension and/or diabetes based on their clinical outcomes 
(systolic blood pressure (SBP) and HbA1c) compared 
with an enhanced care arm using a cluster randomised 
study design.
Secondary objective is to assess the impact of the mWell-
care system on change in cardiovascular risk factors (body 
mass index (BMI), alcohol use, tobacco use) and 10-year 
CVD risk score, mental health status, process outcomes 
and cost-effectiveness.
trial design 
mWellcare is a cluster randomised controlled trial with 
equal allocation of participants between intervention and 
enhanced care arms.
study setting
Twenty clusters each from two states: one in the north 
and the other in the south India have been selected for 
the trial. Each cluster is a Community Health Centre 
(CHC) which caters to a rural population of 120 000 and 
serves as a referral centre for four Primary Health Centres 
(PHCs) in the formal healthcare delivery system.20 CHCs 
were selected from districts covered under the NPCDCS. 
Allocation of the CHCs into intervention and control arm 
is described in the section on randomisation.
Inclusion criteria
Participants aged 30 years and above intending to reside 
in the catchment area of CHCs for at least next 12 months 
were eligible for the trial. Participants were included if 
they were diagnosed case of hypertension with blood 
pressure measuring ≥140/90 mm Hg or type 2 diabetes 
mellitus with fasting blood sugar ≥140 mg/dL or post-
prandial blood sugar ≥200 mg/dL and if they provided 
informed consent.
Exclusion criteria
Pregnant women, patients with type 1 diabetes, patients 
requiring immediate referral to tertiary care due to accel-
erated hypertension or diabetic complications, patients 
with learning difficulties or vision and/or hearing 
impairments, patient suffering from malignancy or 
life-threatening disease with death probable in 4 years 
and patients not residing in the catchment area of the 
CHC were excluded.
Intervention
In the intervention arm, nurse and physician are providing 
treatment and follow‐up to recruited participants using 
mWellcare system. mWellcare system is a tablet comput-
er-based Android application that is designed to store the 
health records electronically, provides decision support 
recommendation tailored to the participant’s compli-
ance and risk level, enables long-term monitoring and 
follow-up and sends SMS reminders (to take medication 
and follow-up visits) to patient. Development of inter-
vention involved adapting existing clinical management 
guidelines to the local context, development and valida-
tion of clinical algorithm and pilot testing of mWellcare 
system. Nurses and physicians in the intervention arm 
were trained in the use of mWellcare system and also 
provided ‘refresher’ training on the clinical management 
guidelines for hypertension and diabetes.
In the intervention arm, besides baseline information, 
the nurse enters information on comorbid conditions: 
depression (using patient health questionnaire 9), 
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alcohol use disorder (using alcohol use disorder iden-
tification test) and previous medication details into 
mWellcare system and generates and prints decision 
support recommendation (DSR) for the physician. 
The DSR printout consists of patient profile, diagnosed 
condition, comorbid conditions, previous and current 
medication and recommended treatment plan. It also 
provides lifestyle change recommendation and the date 
of the next follow-up visit. After review of the DSR, the 
physician may agree or suggest changes in the treatment 
plan which is recorded in the application. Nurse provides 
lifestyle advice brochure (in local language) and explains 
the same to each participant. Each participant will be 
followed up for 12 months. During this period, partic-
ipants will receive SMS reminders for follow-up visits 
scheduled as per clinical algorithm. During follow-up 
visits, nurse enters relevant parameter to the patient’s 
clinical record and generates DSR printout for physician’s 
review. Each intervention site gets monthly reports on 
number of participants reporting for scheduled follow-up 
and average change in clinical parameters.
In the enhanced care arm, nurse and physicians were 
provided ‘refresher’ training on the clinical management 
guidelines for hypertension and diabetes. In addition, 
charts on management of these conditions were provided 
to the facilities for prominent display at the outpa-
tient department. Physicians in the enhanced care arm 
provide the management plan based on their assessment 
of clinical parameters of the participants. Nurse provides 
lifestyle advice brochure (in local language) and explains 
the same to each participant. Follow-up in the enhanced 
care arm is based on the assessment of clinical parameters 
of the participants by the physician.
outcomes
Primary outcomes
 ► Difference in mean change (from baseline to 1 year) 
in SBP between the two treatment arms.
 ► Difference in mean change (from baseline to 1 year) 
glycated haemoglobin (HbA1c) between the two 
treatment arms.
Secondary outcomes include
 ► Difference in mean change (from baseline to 1 year) 
between the two treatment arms for fasting plasma 
glucose, total cholesterol and predicted 10-year risk of 
CVD using recalibrated Framingham risk score.
 ► Differences in risk factors such as depression/anxiety, 
smoking behaviour, BMI and alcohol use between the 
two treatment arms.
 ► Comparison of costs associated with delivering the 
mWellcare intervention arm with respect to enhanced 
care.
Participant timeline
Enrolment and baseline assessment were done during the 
first visit, and the participants were asked to come back 
for blood sample collection (for HbA1C and total choles-
terol tests) within 2 weeks. The intervention started on 
the first visit and will continue for 12 months. After 12 
months, endline assessment will be done.
sample size calculation
The primary outcomes will be analysed as the average 
change of the biomarker (SBP) and glycated haemo-
globin (HbA1c)) from baseline to 12-month follow-up in 
each participant. In each of the trial arms, there will be an 
average change and the effect of the intervention will be 
the difference of these averages.
A recruitment of 40 participants with hypertension per 
cluster in 40 clusters will yield over 98% power with a type 
I error of 5% to detect a mean difference of the change of 
4 mm Hg in SBP, between the intervention and enhanced 
care arm assuming a 15 mm Hg SD of the changes in 
both arms and an intraclass correlation (ICC)=0.05.21 A 
number of 40 participants with diabetes per cluster will 
yield a power above 99% for detecting a true difference in 
average change of HbA1c between the two arms of 0.37%, 
assuming a 1.1% SD of the changes in both arms and an 
ICC=0.04.22 23
All calculations are based on the formula for compar-
ison of two means in cluster randomised trials proposed by 
Hayes and Bennett and assume a 20% loss to follow-up.24
recruitment
For the two primary outcomes (SBP and HbA1c), we 
planned to recruit a total of 90 participants per site with a 
minimum of 45 participants with each conditions: hyper-
tension and diabetes. We estimated that the recruitment 
could be completed in 2 months enrolling a minimum of 
two to three participants a day. However, some sites had 
lower recruitment rate for either of the two conditions. 
Therefore, the final strategy was to stop recruitment of 
participants with either condition after reaching 45, 
and then complete recruitment of patient with the other 
condition. A total of 3702 participants were recruited 
from 40 CHCs.
All individuals diagnosed to have hypertension and/or 
type 2 diabetes were assessed for eligibility by the nurse. 
All eligible participants were invited to participate in 
the trial. After providing written and verbal information 
about the trial, written consent was obtained by the nurse. 
The flow of trial participant is depicted in figure 1.
randomisation
Randomisation units are clusters (CHCs). The randomisa-
tion list was generated by a statistician independent of the 
trial using STATA SE V. 12. The list was stratified by states 
(Haryana and Karnataka) and within states by availability/
non-availability of nurses recruited under NPCDCS. In 
Karnataka, stratification based on availability of nurses 
was done allocating 10 clusters in each category (nurse 
available under NPCDCS/not available). In Haryana, as 
there was no nurses recruited under NPCDCS, further 
stratification was not done. Clusters (CHCs) within each 
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Figure 1 Trial flowchart. AUDIT, Alcohol Use Disorder Identification Test; BP, blood pressure; CHC, community health centre; 
FPG, fasting plasma glucose; NCD, non-communicable disease; PHQ9, patient health questionnaire; PPG, post-prandial 
glucose; SMS, short message service.
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strata were randomised to intervention or enhanced care 
arm using block randomisation (with a block size of 2). 
Being a cluster randomised trial, only limited blinding 
could be enforced. The study statistician will remain 
blinded throughout the study until database is locked and 
study unblinded.
data collection, management and analysis
Baseline assessment
After consent, the nurse in both arms collected base-
line data for the following parameters using a tablet 
computer: age, gender, marital status, occupation, 
alcohol use, smoking behaviour, health-related quality of 
life measured using EuroQol five dimensions question-
naire (EQ-5D), height, weight, blood pressure and blood 
sugar. Consented participants were asked to return on a 
scheduled day for blood sample collection for HbA1c and 
total cholesterol.
Endline assessment
Endline assessment of outcomes will be undertaken after 
completion of 12-month follow-up. The assessments will 
be carried out by independent outcome assessors inviting 
the participants to camps and mop up will be organised 
through home visits.
Data management
This study has only electronic version of the study forms 
and the dataset automatically synchronises with the 
server. There are built‐in data checks and further data 
cleaning will be done by trained data managers at Public 
Health Foundation of India (PHFI), under the super-
vision of the Principal Investigator. All electronic data 
are encrypted, password protected and stored in secure 
computer networks.
Data are monitored centrally for its quality and complete-
ness using electronic validation and on-site monitoring. 
Recruitment and retention of participants was assessed by 
examining the number eligible for recruitment, number 
enrolled in the study and dropout from regular follow-up 
will be assessed at the completion of 12 months. In addi-
tion, we are carrying out central statistical monitoring 
(CSM) all through the trial. CSM aims to detect outliers 
and inliers, deviation of any cluster from the average and 
to detect potential data error or incorrect data collec-
tion procedure. Field coordinators undertake monthly 
visits to all sites, record their observations using Objec-
tive Systematic Structured Observations (OSSO) checklist 
regarding intervention delivery, source documents exam-
ination, protocol adherence and adverse event recording 
and reporting. The monthly visit reports are sent online 
to the research coordinating centre. In addition, study 
investigators undertook site visits to monitor enrolment 
process, intervention delivery and protocol adherence 
and reported to the trial management committee.
Statistical methods
Quantitative data analysis will be performed using STATA 
V. 13.0 (Stata). A statistical data analysis plan will be 
prepared and discussed with Data Safety Monitoring 
Board (DSMB) before data collection is completed.
The primary analyses will be conducted under the prin-
ciple of intention to treat. All randomised participants 
will be analysed in the groups to which they were orig-
inally allocated to, regardless of whether they actually 
retained that specific group membership over the course 
of the trial or not. Participants who withdrew consent for 
use of their data will not be included in any analyses.
Demographic and clinical characteristics will be exam-
ined for participants at each CHC. Summaries will be 
presented as means and SD of those variables that are 
approximately normally distributed, or medians and 
IQRs for skewed variables. Categorical variables will be 
summarised as frequencies and percentages. Transfor-
mations will be used when distributional assumptions are 
not fulfilled for inferential tests on a continuous measure. 
If we find a considerable imbalance in some variables at 
baseline, we will consider adjusting for these variables 
by including them in the model to estimate the effect of 
the intervention. In principle, in a trial with individual 
blinded randomisation, there should be no major base-
line differences between arms, but this may not be the 
case in cluster sample given that the number of samples 
are small, individuals are not completely blind. So there 
is some potential for baseline differences between indi-
viduals recruited in each arm and this will have to be 
adjusted for in the analysis.
We will also account for the influence of clustering 
at the CHC level on the outcome. Data will be analysed 
at the individual level and comparisons will be made 
between the mean changes in the primary outcomes in 
the intervention and control groups. Linear-mixed effect 
models adjusting for baseline measurements will be used 
with a random intercept for the CHC level to account for 
the clustering in the data.
Reporting of results will be in accordance with the 
principles of Consolidated Standards of Reporting Trials(-
CONSORT) statements extended for cluster randomised 
controlled trial (RCT).
Process evaluation
REAIM (reach, effectiveness, adoption, implementation 
and maintenance) framework for the process evalua-
tion will be used for mWellcare trial.25 This would entail 
a combination of qualitative (observations, interviews, 
focus group discussions) and quantitative (open-ended 
and close-ended questionnaires) assessment.
Fidelity will be assessed through logs of training, indi-
cators from OSSO checklist and data captured through 
mWellcare system. Besides reports of monitoring visits by 
experts will form a part of the assessment.
Economic evaluation
To help inform potential financing and adoption of the 
mWellcare intervention, compared with enhanced care 
(control), we will estimate the value for different stake-
holders: patients (mean annual health expenditures 
group.bmj.com on September 19, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
6 Jha D, et al. BMJ Open 2017;7:e014851. doi:10.1136/bmjopen-2016-014851
Open Access 
in each arm), healthcare providers (incremental costs 
to deliver the intervention and cost-effectiveness: eg, 
incremental cost to prevent one CVD event) and society 
(cost-utility: eg, cost per quality-adjusted life years 
gained).
We will collect patient-level healthcare utilisation and 
medical costs data incurred during the trial regarding 
outpatient visits, diagnostic services, medications, 
hospitalisations and lost productivity.26 We will identify 
intervention costs from the non-communicable disease 
clinic and study expenditures (eg, costs related to 
accessing the mWellcare system, and sending the regular 
SMS updates, training costs, labour costs for nurses, 
physician’s time cost and overhead costs minus costs 
attributable only to research activities (eg, annual study 
visit)). We will compute the incremental costs of inter-
vention (implementation, adverse effects, medical care 
associated) compared with control. For effectiveness 
measures, we will use between-group differences in SBP 
and HbA1c reductions. Utility data will be collected using 
the EQ5D Visual Analogue Scale.
If the primary clinical outcomes (SBP and HbA1c) are 
shown to differ substantially, a full economic evaluation 
of the lifetime costs, benefits and cost-effectiveness (in 
life years gained and quality-adjusted life years gained) of 
switching from usual care to mWellcare intervention using 
decision models will be performed.27 Uncertainty around 
incremental cost-effectiveness ratio will be estimated 
using non-parametric bootstrap methods. To inform 
societal perspective, we will calculate an incremental cost-
utility ratio( costsintervention−costscontrolutilityintervention−utilitycontrol).
28 To standardise for the 
time value of money, we will use a 3% annual discount 
rate. Costs will be expressed in rupees and US$ (2016 
value). We will conduct sensitivity analyses where discount 
rates, intervention costs, effectiveness and other model 
parameters will be varied to estimate cost-utility under 
different scenarios.29 We will also generate cost-effective-
ness acceptability curve to demonstrate the probability of 
cost-effectiveness of the intervention at a range of willing-
ness to pay threshold values. If no significant difference is 
found for the primary clinical outcomes, a cost-minimisa-
tion analysis will be performed.
Data monitoring
A four-member DSMB has been established. DSMB 
members are independent from sponsor and have no 
conflict of interest. The board members include experts 
in biostatistics, ethics and cardiovascular disease manage-
ment. Based on observed beneficial or observed effect, 
DSMB will make recommendation to the Research 
Steering Group (RSG) in relation to the conduct of the 
trial (continue, change or terminate). The RSG takes 
responsibility for the design, conduct and analysis of 
the clinical trial. RSG is a multidisciplinary group who, 
collectively, has the scientific, medical and clinical trial 
management experience to conduct and evaluate the 
trial. In addition, a Research Management Committee) 
consisting of principal investigators, co-investigators, 
project manager and other team members have been 
formed to monitor progress of the study.
Serious adverse events
Occurrence of serious adverse events that include severe 
hypoglycaemia, CVD events, diabetes-related gangrene or 
amputation, end-stage renal disease and death is being 
monitored. Information about the occurrence of any 
adverse event is sought at all scheduled visits, and outside 
of scheduled visits by participant self‐report and tracking 
of non‐study-related visits. All events reported in the study 
will be duly notified to the overviewing ethics committees 
and DSMB in the annual progress report.
dIscussIon
mWellcare is the first study in India, assessing the effective-
ness of mHealth technology for integrated management 
of hypertension and diabetes at primary care level in a 
public health setting. Few trials have evaluated the impact 
of DSS on managing patients with hypertension and 
diabetes. A recent cluster randomised trial in Andhra 
Pradesh, India, which evaluated the use of DSS in hyper-
tension management, demonstrated significant reduction 
in SBP among patient in primary healthcare facilities.21 
However, this trial focused only on hypertension while 
the other cardiometabolic risk factors were not covered. 
The recently published results of Cardiometabolic Risk 
Reduction in South Asia (CARRS) Diabetes Trial shows 
significant improvement in diabetes care targets and 
cardiometabolic risk reduction among patients who 
underwent multicomponent quality improvement inter-
vention comprising non-physician care coordinators and 
decision support electronic health records.30 However, the 
findings of CARRS trial are confined to urban specialist 
care settings.
mWellcare trial with its cluster randomised design will 
extend the evidence on impact of mHealth intervention 
on patient’s CVD outcomes at primary care level. It will 
provide evidence on the use of nurse for patient assess-
ment and long-term follow-up using the mWellcare system 
thereby shifting/sharing some of the patient manage-
ment tasks from physicians. It is also designed to provide 
decision support to physician for standardised and inte-
grated management of hypertension and diabetes along 
with comorbid condition such as depression and alcohol 
use disorder.
The mWellcare intervention is being implemented in 
the real-world scenario aimed at using the existing human 
resource (as the nurse appointed at the outpatient clinics 
through the NPCDCS). The trial also incorporates cost-ef-
fectiveness analysis of the intervention. All these factors 
would be helpful in informing decision makers in allo-
cating resources and scaling up the intervention based on 
the trial findings.
There are a few limitations for this study. The effec-
tiveness of the trial will also depend on the availability of 
drugs, recommended by the decision support system, at 
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the CHCs. Drugs are supplied by the state government 
and there are variations in availability across the state and 
districts, although such variations are likely to affect both 
arms equally. Another limitations is that the mWellcare 
system will be used only for the people who have been 
already diagnosed with hypertension or diabetes by the 
physician, and will not aid in opportunistic screening of 
patients coming to the CHC. This was done to keep both 
intervention and control arms at par. In case the interven-
tion is scaled up, a screening module can be added to the 
mWellcare system.
conclusion
The mWellcare trial will provide evidence on effec-
tiveness of the nurse-based mHealth intervention for 
integrated management of hypertension and diabetes at 
primary care level in India. Results from the trial will have 
direct policy relevance in adopting mHealth solution for 
managing CVDs at primary care level in India.
EthIcs And dIssEMInAtIon
 mWellcare trial protocol and study documents have been 
approved by the Institutional Ethics Committee at PHFI 
and London School of Hygiene and Tropical Medicine. 
All information collected as part of this study will be kept 
strictly confidential. Personal identifiers will be removed 
before transferring data for analysis. Participant’s identity 
will be anonymous and postanalysis of the data, the tapes 
and transcripts will be destroyed. Participant’s name or 
identity will not be revealed in any of the publications 
arising from this research.
Findings from this study will be submitted for publica-
tion in peer-reviewed journals. The study results will be 
shared with health professionals (primary care providers), 
local government and decision makers as brief policy 
notes. The study investigators will also disseminate find-
ings through professional conferences targeting primary 
and secondary care physicians, research community and 
public health policymakers more widely. The results of 
this study will provide policy-relevant recommendations 
for the uptake of mHealth interventions in the manage-
ment of hypertension and diabetes in India.
At the end of the study, the investigators will form a 
Publication, Presentation and Ancillary Studies (PP&A) 
subcommittee, which will develop a suitable policy 
protecting the rights of involved organisations regarding 
ownership of study materials and data. The full editorial 
control will reside with the PP&A committee. All investi-
gators will be given access to the cleaned data sets.
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